Amantadine

Chronic respiratory disease is the 3rd most common cause of death, accounting for 16% of all deaths 89, 000 deaths per year ; . It causes 13% of adult disability, of which the greatest cause is chronic obstructive pulmonary disease COPD ; Edmonds et al 2001 ; . Studies have shown that patients with end-stage respiratory disease have unmet physical, psychosocial and spiritual needs and would greatly benefit from the holistic palliative care approach Claessens et al 2000; Gore at al 2000; Hill & Muers 2000; Edmonds et al 2001. Reduce the emergence of antiviral drug-resistant viruses, amantadine or rimantadine therapy should be discontinued as soon as clinically warranted, typically after 3-5 days of treatment or within 24-48 hours after the disappearance of signs and symptoms. Side effects of both medications can include: nervousness, anxiety, difficulty concentrating, lightheadedness, and insomnia. Central nervous system side effects occur more frequently among persons taking amantadine than among those taking rimantadine. Zanamivir and oseltamivir are members of a new class of drugs called neuraminidase inhibitors, and are active against both influenza type A and type B. Although not FDA approved for prophylaxis, zanamivir is as effective as oseltamivir for influenza prophylaxis, according to the ACIP. Zanamivir is FDA approved for treatment of uncomplicated acute influenza A or B persons 7 years of age and older who have been symptomatic for no more than 2 days. Side effects of zanamivir include decreased respiratory function and bronchospasms. It is not recommended for use in individuals with underlying airway disease. Oseltamivir is approved for prophylaxis of influenza infection among persons 13 years. It is approved for the treatment of uncomplicated influenza A or B persons 1 year of age and older who have been symptomatic for no more than 2 days. Side effects reported most often in individuals taking oseltamivir include nausea and vomiting. Zanamivir and oseltamivir have been shown to reduce the duration of uncomplicated influenza A and B illness by approximately 1 day. The recommended duration of treatment with either zanamivir or oseltamivir is 5 days. None of the four antiviral agents has been demonstrated to be effective in preventing serious influenza-related complications such as bacterial or viral pneumonia. It is also important to note that antiviral agents are an adjunct and not a substitute for vaccine. Vaccination remains the principal means for preventing influenza-related morbidity and mortality. The Advisory Committee of the Health and Medical Subpanel of the Secure Virginia Panel will make recommendations for use of antiviral agents based on availability during an actual pandemic. Table 3 addresses the antiviral agents currently available and their current approved use for prophylaxis and or treatment. Table 3. Antiviral Agents for Prophylaxis and Treatment of Influenza Antiviral Agent Aman5adine Rimantadine Zanamivir Oseltamivir Trade Name Symmetrel Flumadine Relenza Tamiflu Flu Type A A A and B A and B Use Prophylaxis Treatment Prophylaxis Treatment Treatment only Prophylaxis Treatment Age Restrictions 1 year Adults only for treatment 1 year for prophylaxis 7 years 1 year for treatment 13 years for prophylaxis. To the proximal colon, J. Pharmacol, 37: 874-877, 1985.
Inhibit SSAT acetylation of spermidine. SMZ demonstrated the ability to inhibit SSAT activity in a concentration-dependent manner r2 0.99, n 4 ; , which provides preliminary evidence that NAT2selective substrates may also serve as substrate for SSAT data not shown ; . However, the calculated Ki of 3.5 mM in this species suggests the effect will not be clinically relevant. In contrast, PABA, an NAT1-selective substrate, showed no SSAT inhibition r2 0.23, n 5 ; data not shown ; . Amantadlne Acetylation. Transgenic mouse liver supernatant, containing overexpressed SSAT and incubated with three concentrations of amantadine in the presence of an acetyl CoA-regenerating. Study design: - Questionnaire-based evaluation via Metab-l ; of current practice of oral Lcarnitine supplementation in MCAD deficiency, propionic PA ; and methylmalonic acidurias MMA glutaric aciduria type I was only included into the discussion. - Literature review PubMed ; : evaluation.

What is amantadine used for Medical Article References Arranged by Year Published ; Stoll BA: Hormone Replacement Therapy in Women Treated for Breast Cancer. Eur. J. Cancer Clin. Oncol 1989: 25: 1909. Wile AG, DiSaia PJ: Hormones and Breast Cancer. J Surg J Surg 1989; 157: 438. Bergkvist L, Adami H, Persson I, et al. Prognosis after Breast Cancer Diagnosis in Women Exposed to Estrogen and Estrogen-Progesterone Replacement Therapy. J Epidemiol. 1989; 130: 221-228. Creasman WT: Estrogen Replacement Therapy: Is Previously Treated Cancer a Contraindication? Obstet Gynecol 1991: 77: 308 Vassilopoulou-Sellin R, Zolinski C. Estrogen Replacement Therapy in Women with Breast Cancer: A Survey of Patient Attitudes. J Med Sci. 1992; 304 3 ; : 145-149. Vassilopoulou-Sellin R. Estrogen Replacement Therapy for Breast Cancer Survivors, Rationale for a Prospective, Randomized Trial. Female Patient 1993; 18: 41-48. Speroff L. Postmenopausal therapy and the risk of breast cancer. Maturitas. 1999; 32: 123-129. Speroff L. Hormone Replacement and Breast Cancer. Supp to The Female Patient, Dec.2001. Pritchard, K et al. Clinical Practice Guidelines for the Care and Treatment of Breast Cancer: 14. The Role of Hormone Replacement Therapy in Women with a Previous Diagnosis of Breast Cancer. Canadian Medical Association Journal. April, 2002; 166 8 ; . Grady, Deborah, et al. Noncardiovascular Disease Outcomes During 6.8 Years of Hormone Therapy Heart and Estrogen Progestin Replacement Study Follow-Up HERS II ; . JAMA, July 3, 2002; 288: Rossouw, Jacques E., et al. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. Principal Results from the Woman's Health Initiative Randomized Controlled Trial. JAMA July 17, 2002; 288: Lea, Robert et al. Use of Hormonal Replacement Therapy After Treatment of Breast Cancer. JOGC, Jan. 2004; 142: 49-54 von Schoultz E, Rutqvist LE. Menopausal Hormone Therapy after Breast Cancer: The Stockholm Randomized Trial. Journal of the National Cancer Institute 2005; 97 7 ; : 533535. 3 and zofran. Vaccines to protect humans against H5N1 viruses currently are under development. In addition, research is underway on methods to make large quantities of vaccine more quickly. So far, research suggests that two antiviral medicines, oseltamavir Tamiflu ; and zanamavir Relenza ; , may be useful treatments for H5N1 avian influenza. However, H5N1 viruses are generally resistant to two other available antiviral medications, amantadine and rimantadine, so they cannot be used to treat avian flu. Attenuating excessive outflow of the neurotransmitter that is responsible for HD hyperkinesias. Clinical trials of tetrabenazine have shown its efficacy with respect to attenuating the chorea of HD patients Soutar, 1970; Toglia et al., 1978; Jankovic and Beach, 1997 ; . Apomorphine, which can cause effective reductions in the levels of dopamine release from neurons has also shown some efficacy in HD symptomology control Caraceni et al., 1980 ; . As with many other neurodegenerative disorders, the excitoxicity paradigm has been invoked for HD. Hence the excessive pathological excitatory actions of synaptic glutamate transmission may underlie the early generation of neuronal dysfunction DiFiglia, 1990 ; . In the central nervous system glutamate can activate either ionotropic NMDA, AMPA or kainic acid ; or metabotropic mGluR ; glutamate receptors. Several NMDA receptor ion channel-blocking antagonists have been clinically tested for their neuroprotective effects. Amanyadine was demonstrated to effectively lower chorea symptoms VerhagenMetman et al., 2002 ; . However this compound has negative effects upon other neuronal conditions, i.e. increasing irritability and aggressiveness in HD patients Stewart, 1987 ; . Remacemide, like amantadine, also reduced chorea symptoms Bodner et al., 2001 ; but failed to demonstrate any significant neuroprotective action Bonelli and Niederwieser, 2002 ; . Another promising glutamate receptor agent for HD is the NMDA receptor functional antagonist Memantine Lipton, 2004 ; . This compound has also been used to treat other forms of neurodegenerative disorders such as Alzheimer's disease. Perhaps the most efficacious glutamate receptor antagonist for HD appears to be Riluzole as this was better tolerated during trials than the two previous compounds Wu et al., 2006 ; . Corroborating the role of excitotoxicity in HD etiology it has been demonstrated that there is a reduction of gamma amino butyric acid GABA ; in both brain tissue and cerebrospinal fluid of HD patients CSF: Perry et al., 1973; Glaeser et al., 1975 ; . The inhibitory GABA acts as a functional brake upon excessive stimulatory glutamate receptor activation. Therefore a diminution of GABAergic neurotransmission may lead to the generation of widespread excitotoxicity. To redress this neurotransmitter imbalance, GABA receptor agonists such as baclofen could have therapeutic value. Baclofen has been shown to reduce the choretic activity in HD patients Anden et al., 1973 ; . In addition chemical precursors of GABA L-glutamate and pyridoxine ; , which increase the levels of GABA in nerve terminals, have been shown to alleviate HD motor dysfunction Barr et al., 1978 ; . Agents capable of inhibiting the breakdown of GABA Isoniazid ; have also been tested for their efficacy in HD. Isoniazid can effectively elevate and reminyl.

Amantadine generic name However, to be most cost-effective, amantadine or rimantadine prophylaxis should be taken only during the period of peak influenza activity in a community. A booming Massachusetts life sciences industry has added about 800 jobs this year and is planning to occupy an additional 1 million square feet of laboratory and office space according to a November report by the real estate company NAI Hunneman Commercial. "Over the past twelve months, the life sciences industry has experienced an enormous wave of financing, mergers and acquisitions, and regulatory approval activity, " said NAI Hunneman senior VP Greg Larsen. "Coupled with the fact that companies continue to be attracted to collaborative opportunities.with other life science players within the area, it only makes sense that more companies are choosing Massachusetts as the base for their high-tech research and development operations, " he added. The most recent estimates are that biotech employs 30, 000 in the state, with another 20, 000 employed in the medical device industry. The report also underscores a dramatic turnaround in the Cambridge lab market. Two years ago, vacancies ran at 26.2 percent for lab and R&D space. In the second quarter of this year, the vacancy rate had dropped to 11.5 percent. Source: Jeffrey Krasner, The Boston Globe, 2 November 2006 and revia. Amantadine should the pneumonia injuries were increased.

Table 3. Dosing guidelines of adjuvant analgesics continued ; Drug N-methyl-D-aspartate receptor antagonists Ketamine Dextromethorphan Mantadine Symmetrel ; Adjuvant analgesics for bone pain Corticosteroids Calcitonin Miacalcin ; Bisphosphonates Pamidronate Aredia ; Zoledronic acid Zometa ; Radiopharmaceuticals Downloaded from TheOncologist by on October 16, 2007 Adjuvant analgesics for musculoskeletal pain Muscle relaxants Cyclobenzaprine Flexeril ; Orphenadrine Norflex ; Carisoprodol Soma ; Metaxalone Skelaxin ; Methocarbamol Robaxin ; Tizanidine Baclofen Benzodiazepines Diazepam Valium ; Lorazepam Ativan ; Clonazepam Klonopin ; Adjuvant analgesics for pain from bowel obstruction Octreotide Sandostatin ; Anticholinergics Hyoscine scopolamine ; Glycopyrrolate Robinul ; Corticosteroids Dexamethasone Decadron ; Methylprednisolone Solu-Medrol ; Other adjuvant analgesics Baclofen Lioresal ; Cannabinoids Dronabinol Marinol ; Psychostimulants Methylphenidate Metadate CD; Methylin; Ritalin ; Modafinil Provigil and dramamine. In general terms, experimental models are a part of strategy that is employed to develop new and better therapeutic agents for a particular ailment Figure 1.2 ; . The experimental models are developed based on pathophysiological features of the disease and the pharmacological action of the existing drugs. The new compounds found active in the models are subjected to clinical evaluation. If the compound is devoid of clinical efficacy and pharmacokinetic reasons are excluded, the model must be modified or discarded. On the other hand, when the compound is found clinically effective, it not only benefits patients, but further evaluation of its pharmacology leads to modification of experimental models and, in some cases, to entirely new models that may yield new compounds ultimately becoming novel therapeutic agents. You can find dozens of books and thousands of journal articles about herpes at any university research library. The most informative sources of information for the public are available by phone or by Internet. The government-supported Center for Disease Control and Prevention in Atlanta offers updated information on the occurrence of many viral diseases in the U.S. The CDC's phone numbers for public inquiries are 404 ; 639-3534 and 800 ; 311-3435. This is the computer age, so you can also reach the CDC via Internet : cdc.gov ; . If the CDC is too bureaucratic for you, your best recourse is to get onto the information highway and surf the Internet. By late 1996 a search using `herpes' as the keyword on a major search engine found more than 15, 000 documents; by early 1999 this had increased to over 105, 000, and by the second half of 2003 it had reached more than 1 million. One of the best websites found by such searching is the Herpes Resource Center, which is hosted by the American Social Health Association. This site may be the most comprehensive information resource about and parlodel. 0 Should be class III until more safety and efficacy data available. Does not believe that evidence is compelling enough Closed venous system is safer and better for blood conservation based on personal observation. Need to separate type of reservoir from type of oxygenator. Centrifugal pumps are standard of care. NICE guidance and Oseltamivir In July 2003, the National Institute of Clinical Excellence NICE ; published final guidance subject to appeal ; on the use of oseltamivir and amantadine for the prophylaxis of influenza 15 ; . Oseltamivir is recommended for the post-exposure prophylaxis of influenza in at-risk individuals aged 13 years or over who are not effectively protected by vaccination, and have been exposed to someone with influenza-like illness ILI ; in the same household. In addition, oseltamivir is recommended for the post-exposure prophylaxis of influenza in at-risk individuals aged 13 years or over, who are able to begin prophylaxis within 48 hours of exposure, whether or not they have been vaccinated, if they live in residential care establishments where a resident or staff member has influenza-like illness. Oseltamivir is not recommended for post-exposure prophylaxis in healthy people aged under 65 years, or for seasonal prophylaxis, while amantadine is not recommended for either postexposure or seasonal prophylaxis. Vaccine recommendations In March 2003 the WHO announced the recommended vaccine components for the 2003 2004 winter season in the northern hemisphere. The recommended components for the 2003 2004 vaccine for the northern hemisphere are 10 and hydrea.
Drugs to treat viral illnesses are relatively new as a class. Although Symmetrel amantadine ; was approved in 1966 for Parkinsonism, its additional indication for treating influenza was not granted until 1976. The first AIDS drug, Retrovir zidovudine, AZT ; , was approved in 1987. The alpha interferons Intron-A, Roferon ; were approved in the mid-1980s for cancers and the early 1990s for hepatitis.
The web -site of the book is : fda.gov cder orange default ; More precisely, each record in the Approved Drug Products file of The Book contains the active ingredient s ; for the product, dosage, route of administration, strength, the firm holding legal responsibility for the new drug application, and the approval Date The date the product was approved as stated in the FDA approval letter to the applicant. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982". ; , and the therapeutic equivalence TE ; code; the TE Code indicates the therapeutic equivalence rating of generic to brand-name drugs and dilantin.

Of estrogen and bisphosphonates together had a greater impact on BMD gains as compared to either agent alone Bone et al., 2000 ; . Moreover, the combination of calcium, exercise and HRT was evaluated in some studies, where it was shown that estrogen combined with weight-bearing exercises Kohrt et al., 1995 ; or resistance exercise Notelovitz et al., 1991 ; or even weight bearing plus calcium Prince et al., 1991 ; acted better than either treatment alone. An attractive combination to increase bone strength would be to increase BMD by one of the anti-resorptive agents and to improve bone geometry and architecture by exercise Uusi-Rasi et al., 2003 ; . Further studies with fractures as an endpoint need to be implemented before recommending combination therapy to patients with osteoporosis. It is important to note that HRT is no longer viewed as the `gold standard' therapy for osteoporosis Compston, 2000 ; owing to the other emerging anti-resorptive and anabolic treatments. 2.8.4. Exercise Exercise is an important component for a healthy well-being throughout the life cycle; from maximizing peak bone mass during childhood and adolescence, to maintaining or increasing BMD in pre and postmenopausal women, to increasing muscle strength, muscle mass and improving balance in elderly, exercise should be incorporated in everyone's daily routine. Weight-bearing and resistance training appear to be the first-line exercises that show benefits on BMD in the aging population. Yet, weight-bearing activities walking ; that decrease the risk of trauma may represent a more adequate regimen for elderly males and females who cannot afford lifting weights. Regardless of changes in BMD, the overall benefits of physical activity on the muscles may end up reducing the risk of falling Lewis and Modlesky, 1998 ; . Toned muscles may also prevent trauma to the bones Kuntze et al., 1989 ; . Conversely, excessive exercise can.

Blood Clear with Lab Resident. Blood Biochemical disease detection laboratory. WWW 313. For additional information call 5-2662 and docusate. 1. Nicholson KG, Wiselka MJ. Amsntadine for influenza A. Br MedJ 1991; 302: 425 Smith JP. Treatment of chronic hepatitis C with amantadine. DigDis Sci 1997; 42: 16817. Brillanti S, Foli M, Di Tomasi M, et al. Pilot study of triple therapyfor chronic hepatitis C in interferon alpha non-responders.Ital J Gastroenterol Hepatol 1993; 31: 1304. Findor JA, Daruich JR, Bruch Igartua E, et al. Amantadine HCL alone, and associated with recombinant alpha IFN 2a during a short term therapy in chronic HCV infection. Hepatology 1997; 26: 217A. Fang JC, Hespenheide EE, Driscoll CJ, et al. Amantadine-HCL treatment of chronic hepatitis C. Hepatology 1997; 26: 217A. Khalili M, Denham C, Perrillo R. Interferon and ribavirin versusinterferon and amantadine in interferon nonresponders with chronic hepatitis C. J Gastroenterol 2000; 95: 1284 Yang S-S, Tu T-C, Wu C-H. Combination of interferon alfa-2a and amantadine does not improve the efficacy of interferon therapy in patients with chronic hepatitis C. Hepatology 1999; 30: 369A. Zeuzam S, Teuber G, Naumann U, et al. Randomised, doubleblind, controlled trial interferon-alfa with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 1999; 30: 200A. Brown PJ, Neuman mg. Digestive Disease Week 2000 conference report: New treatments for chronic hepatitis C. Can J Clin Pharmacol. 2001 Summer; 8 2 ; : 67-71. 10. Mangia A, Minerva N, Annese M, Leandro G, Villani MR, SantoroR, Carretta V, Bacca D, Giangaspero A, Bisceglia M, Ventrella F, Dell'Erba G, Andriulli A. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology. 2001 Apr; 33 4 ; : 989-93. 11. Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, SidoliL, Caronia S, Foster GR, Zeuzem S, Berg T, Di Marco V, Cino N, Andriulli A. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from six clinical trials. J Hepatol. 2004 Mar; 40 3 ; : 478-83. 12. Smith JP, Riley TR 3rd, Bingaman S, Mauger DT. Amantadine therapy for chronic hepatitis C: a dose escalation study. J Gastroenterol. 2004 Jun; 99 6 ; : 1099-104. 13. Teuber G, Pascu M, Berg T, Lafrenz M, Pausch J, KullmannF, Ramadori G, Arnold R, Weidenbach H, Musch E, Junge U, Wiedmann KH, Herrmann E, Zankel M, Zeuzem S. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol. 2003 Oct; 39 4 ; : 606-13. 14. Thuluvath PJ, Maheshwari A, Mehdi J, Fairbanks KD, Wu LL, Gelrud LG, Ryan MJ, Anania FA, Lobis IF, Black M. Randomised, double blind, placebo controlled trial of interferon, ribavirin, and amantadine versus interferon, ribavirin, and placebo in treatment naive patients with chronic hepatitis C. Gut. 2004 Jan; 53 1 ; : 130-5. On April 25, 2003, Sankyo concluded an agreement with Sanwa Kagaku Kenkyusho Co., Ltd., for the co-promotion of Kremezin, a drug for the treatment of chronic renal failure developed by Kureha Chemical Industry Co., Ltd. Under the agreement, Sankyo is handling sales. Through this partnership with Sanwa, Sankyo aims to bolster awareness of the drug's efficacy in treating chronic renal failure and zometa and Order amantadine!

5. Erythrocyte sedimentation rate speed at which red blood cells settle after an anticoagulant has been added to a blood sample and lamictal.
Are not able to get enrollment for licensing practice. The discussion is going on amending this clause and incorporate training component to upgrade their knowledge and bring them into the main stream. Academic Institutions: The first formal technical education started in the country was in Ayurveda. In 1928 AD Nepal Rajakiya Ayurveda Vidyalaya was started in Naradevi, Kathmandu for the production of Ayurveda manpower i.e. Vaidyas of all levels up to Acharya, equivalent to a Bachelor of the present day standards in contrast to the technical education in the modern system. In spite of the fact that Ayurveda is traditional and that formal education began much earlier than arrival of the modern medical system, since the advent of "democracy" in 1950, the emphasis and all out efforts has been on the modernization and expansion of modern health services. Ayurveda Campus TU is the continuing institute of Ayurveda Vidhyalaya. Other training Institutes under Mahendra S. University and CTEVT in the periphery are running. At present, one graduate level Ayurveda College, seven three-years- course educational institutions, and three fifteenmonth tranining institutions are running legally throughout the country. Ayurveda Pharmaceutical Sector: There is one government owned producing unit, Singha Durbar Baidhyakhana Vikas Samiti started from Malla dynasty 357 years ago with a high reputation in its history ; running below capacity and constraints of quality measures. There are 32 other private Ayurveda pharmaceutical companies, with limited capacity and some of them are not functioning all of the time. National Ayurveda Research & Training Centre: Governments of Nepal & China have signed recently for the establishment of this institute and this is a recent development in Ayurveda sector in Nepal. Other: There are a significant number of institutions - Public, Development Partners', I NGO and Private Organizations and Institutions involved in Medicinal plants including NTFPT - involved in this sector. There is minimal coordination within the Ayurvedic sector, which is very important and vital for the overall development of the country and Intellectual property rights issues. Status of traditional medicine: A glance System Manpower Graduated post graduated Ayurveda 239 Homeopathy Other.
Amantadine versus placebo; however, both the white blood cell count and bilirubin levels remained within the normal range in both groups. There was no statistically significant difference between the 2 treatment groups in regard to other blood values, including blood urea nitrogen, serum creatinine, alkaline phosphatase, albumin, or prothrombin time.

Generated outside France, compared to 27% in 1998. The Publishing businesses contributed 4354.5 million to operating income in 1999, an increase of 4102.3 million from 1998, primarily due to acquisitions described above. Internal growth was three percent resulting largely from productivity enhancements in our French operations. TV & Film Vivendi Universal's TV & Film businesses are a major global player in lm and television production and distribution, pay television channels and services, digital television technology, Internet content and themed entertainment. The TV & Film businesses own the world's second-largest lm and television library, totaling more than 8, 600 feature lms and more than 30, 000 hours of TV programs. The TV business is comprised of CANAL and Universal Television and Networks Group. CANAL is the leading European producer and operator of pay television premium and theme channels, the number one in Europe in digital television and also is an international provider of digital TV solutions. Universal Television and Networks Group is a global television sales, networks and production operation, with customers in over 180 countries. The Film business is comprised of Universal Pictures and StudioCanal which produce and distribute motion picture, television and home video DVD, products worldwide and engage in the licensing of merchandising and lm property rights. Universal Studios Recreation Group operates the themed entertainment business, which is a natural extension of the core TV & Film businesses. Its ""Universal Studios'' destination resorts, theme parks and entertainment centers provide exciting and compelling attractions to visitors around the world. Through Universal Studios, Vivendi Universal has an eective 43% equity interest in USA Networks, Inc., which is focused on the new convergence of entertainment, information and direct selling. Formed in February 1998, the company is organized into three distinct but interrelated units: entertainment, electronic retailing and information and services. 2000 Versus 1999 Restated ; Actual. Revenue from the TV & Film segment totaled 44.2 billion in 2000, of which 43.8 billion was generated by CANAL and 40.2 billion was generated by Universal Studios in the twenty-three day period following the merger. Revenue growth for CANAL was 17%, with 13% growth in pay TV. All divisions contributed to the revenue growth. Of the total TV & Film revenue, 42.7 billion were generated in France and 41.5 billion were generated outside France. At December 31, 2000, CANAL had 15.3 million subscriptions, an increase of nine percent over the prior year. The number of digital subscribers increased 32% in 2000, to 5.3 million. In spite of increased subscriptions and digital subscribers and several hits from StudioCanal, the CANAL operating loss increased to 498 million in 2000 from a 422 million loss in 1999 on a full year basis. The increased loss was primarily due to investment in the Italian pay television market, sports rights and competition in Europe, which increased expenses aimed at reinforcing subscriber loyalty and the move towards digitalization. This was partly oset by positive operating results at StudioCanal and CanalSatellite. Pro forma. Pro forma results include the operations of Universal Studios on a twelve-month calendar year basis and the consolidation of CANAL for twelve months in 1999. Pro forma EBITDA more than doubled to 4770.9 million, on revenue of 48.8 billion, largely due to strong box oce performance at Universal Studios and a solid subscriber base in the pay television market. The performance of Universal Studios improved year-on-year. In 2000, revenue increased 23% six percent on a constant rate basis ; to 44.7 billion, operating income was 47 million, an increase of 4282 million, and EBITDA was 4241 million, an increase of 4337 million. These results reect improvements in both the lmed entertainment and recreation and other businesses. Within the lmed entertainment business, revenue increased 22% ve percent on a constant rate basis ; , and EBITDA was 470 million, an improvement of 4281 million compared to 1999. These results primarily reect the solid performance of the motion picture business in 2000. The theatrical success of Dr. Seuss' How The Grinch Stole Christmas, Gladiator, Meet the Parents, Erin Brockovich and Nutty Professor II: The Klumps, combined with strong DVD and video sales of The Mummy, Notting Hill and American Pie resulted in improved earnings. Additionally, the development of programs designed to manage production, marketing, participation and overhead and development costs also contributed to lmed entertain65!

Amantadine add

Amantadine hcl 100mg

What is amantadine used for, amantadine generic name, amantadine add, amantadine hcl 100mg and amantadine ld50. Amantadine canine use, what are side effects of amantadine, amantadine tamiflu and amantadine parkinson disease or ribavirin amantadine hepatitis.

Amantadine ld50

Mary j blige growing pains uk edition, hemihypertrophy surgery, glycohemoglobin procedure, leaf abscission and auxin and colonic bleeding. Buy admission essays, contrast training, zyvox iv cost and familial neoplasia or oxcarbazepine medication.